Induction of N-Ras degradation by flunarizine-mediated autophagy

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Ras GTPases, including N-Ras, are critical oncogenes driving tumorigenesis.
• Targeting Ras proteins for cancer therapy has proven challenging.
• Basal-like breast cancer (BLBC) is an aggressive subtype driven by N-Ras.

Purpose of the Study:

• To identify existing drugs that induce N-Ras degradation for cancer treatment.
• To investigate the mechanism of N-Ras degradation induced by identified compounds.
• To evaluate the therapeutic potential of N-Ras degradation in BLBC.

Main Methods:

• Screened pharmacologically active compounds for N-Ras degradation-inducing activity.
• Utilized proteasome and autophagy inhibitors to elucidate the degradation pathway.
• Performed in vitro cell growth assays and in vivo xenograft studies in BLBC models.

Main Results:

• Identified flunarizine (FLN) as an inducer of N-Ras degradation via the autophagy pathway, not the proteasome.
• FLN selectively inhibited the growth of BLBC cells in vitro, mimicking N-RAS silencing.
• FLN demonstrated efficacy in inhibiting BLBC tumor growth in vivo xenograft models.

Conclusions:

• The autophagy pathway can be targeted by small molecules like FLN to degrade Ras proteins.
• FLN represents a novel therapeutic strategy for targeting N-Ras-driven cancers, particularly BLBC.
• FLN exhibits low toxicity and warrants further investigation as a potential cancer therapeutic.